Novartis-AveXis : A ‘gene’-ius deal?

anonymous

Guest

anonymous Apr 10, 2018 at 07:11: AM

#1

anonymous

Guest

Novartis is wagering high on gene therapy with its proposed acquisit ion of AveXis Inc. valued at $8.7 billion. The high-premium deal is expected to be completed in mid-2018. Source https://news.alphastreet.com/novartis-avexis-a-gene-ius-deal/
"The pharmaceutical sector is witnessing many interesting deals as companies look to partner with each other to expand their portfolios and bolster their capabilities."

anonymous

Guest

anonymous Apr 10, 2018 at 09:21: AM

#2

anonymous

Guest

I think is a step in the right direction for the future.

anonymous

Guest

anonymous Apr 10, 2018 at 09:32: AM

#3

anonymous

Guest

After the divestiture of our CHC business and a string of deals / acquisitions in field of gene therapy and some others innovative approaches the risk profile of our portfolio has increased significantly. Five to ten years from now we either rise to the top of the most innovative pharma companies making it on the covers of the most trusted journals and newspapers or we will have disappeared or at least marginalized because we sunk all that money in too risky deals and futile R&D investments.

anonymous

Guest

anonymous Apr 10, 2018 at 01:29: PM

#4

anonymous

Guest

Most of the candidates for the AveXis commercial field positions have backed out because of this deal.

The recruiter will likely open up the candidate pool to big pharma robots.

anonymous

Guest

anonymous Apr 11, 2018 at 12:08: PM

#5

anonymous

Guest

I'm currently a biologics rep

Obviously I'm cleverer than most reps but I'm not sure I'm clever enough to sell 'genics'

Is there a test I can take to check my chances?

Come what may really excited about this bold step from a bold new regime !!!